Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Highly Accessed Editorial

Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?

Anne C Armstrong and David E Gilham*

Author Affiliations

Clinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Healthcare Science Centre, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester, M20 4BX, UK

For all author emails, please log on.

Breast Cancer Research 2012, 14:106  doi:10.1186/bcr3184


See related research by Wang et al., http://breast-cancer-research.com/content/14/2/R39

Published: 30 May 2012

Abstract

The central goal of cancer immunotherapy is to control tumors through the mobilization of the patient's immune system. Vaccines targeting the Her2/neu proto-oncogene have been tested with some early encouraging responses in breast cancer. However, a more effective set of vaccines targeting specific immune cell subtypes may provide a more potent means to stimulate anti-tumor immunity. Dendritic cell-specific antibodies fused with the Her2/neu protein proved effective at generating immune responses in preclinical models. Importantly, only low amounts of protein vaccine were required to generate this response, which has potentially significant implications for the future clinical development of Her2/neu-targeted vaccines and other vaccine targets.